IPSEN (IPN.PA) Stock Fundamental Analysis
Europe - EPA:IPN - FR0010259150 - Common Stock
130.5 EUR
+0.3 (+0.23%)
Taking everything into account, IPN scores 6 out of 10 in our fundamental rating. IPN was compared to 54 industry peers in the Pharmaceuticals industry. IPN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IPN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IPN was profitable.
IPN had a positive operating cash flow in the past year.
IPN had positive earnings in each of the past 5 years.
IPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.56%, IPN is in line with its industry, outperforming 57.41% of the companies in the same industry.
Looking at the Return On Equity, with a value of 10.59%, IPN is in line with its industry, outperforming 55.56% of the companies in the same industry.
IPN has a better Return On Invested Capital (14.88%) than 75.93% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IPN is in line with the industry average of 14.87%.
The last Return On Invested Capital (14.88%) for IPN is above the 3 year average (12.97%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROIC | 14.88% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
1.3 Margins
IPN's Profit Margin of 11.91% is in line compared to the rest of the industry. IPN outperforms 51.85% of its industry peers.
In the last couple of years the Profit Margin of IPN has declined.
IPN's Operating Margin of 26.01% is fine compared to the rest of the industry. IPN outperforms 62.96% of its industry peers.
In the last couple of years the Operating Margin of IPN has declined.
IPN has a Gross Margin of 83.32%. This is amongst the best in the industry. IPN outperforms 90.74% of its industry peers.
In the last couple of years the Gross Margin of IPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% |
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IPN is creating value.
The number of shares outstanding for IPN has been increased compared to 1 year ago.
IPN has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for IPN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.58 indicates that IPN is not in any danger for bankruptcy at the moment.
IPN has a Altman-Z score of 4.58. This is in the better half of the industry: IPN outperforms 66.67% of its industry peers.
IPN has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
IPN's Debt to FCF ratio of 1.69 is amongst the best of the industry. IPN outperforms 88.89% of its industry peers.
IPN has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
IPN has a Debt to Equity ratio of 0.20. This is in the better half of the industry: IPN outperforms 75.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 4.58 |
ROIC/WACC1.89
WACC7.89%
2.3 Liquidity
IPN has a Current Ratio of 1.98. This is a normal value and indicates that IPN is financially healthy and should not expect problems in meeting its short term obligations.
IPN's Current ratio of 1.98 is fine compared to the rest of the industry. IPN outperforms 75.93% of its industry peers.
A Quick Ratio of 1.80 indicates that IPN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.80, IPN belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 12.24% over the past year.
IPN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.79% yearly.
The Revenue has grown by 9.45% in the past year. This is quite good.
IPN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.83% yearly.
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
3.2 Future
IPN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.58% yearly.
The Revenue is expected to grow by 4.58% on average over the next years.
EPS Next Y6.71%
EPS Next 2Y3.8%
EPS Next 3Y4.44%
EPS Next 5Y5.58%
Revenue Next Year8.23%
Revenue Next 2Y6.1%
Revenue Next 3Y6%
Revenue Next 5Y4.58%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 12.71, which indicates a correct valuation of IPN.
Based on the Price/Earnings ratio, IPN is valued a bit cheaper than the industry average as 74.07% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.35, IPN is valued rather cheaply.
IPN is valuated reasonably with a Price/Forward Earnings ratio of 11.79.
Based on the Price/Forward Earnings ratio, IPN is valued a bit cheaper than the industry average as 75.93% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.72, IPN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.71 | ||
| Fwd PE | 11.79 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IPN indicates a rather cheap valuation: IPN is cheaper than 92.59% of the companies listed in the same industry.
IPN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IPN is cheaper than 62.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.21 | ||
| EV/EBITDA | 6.01 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IPN does not grow enough to justify the current Price/Earnings ratio.
IPN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.89
PEG (5Y)1.45
EPS Next 2Y3.8%
EPS Next 3Y4.44%
5. Dividend
5.1 Amount
IPN has a Yearly Dividend Yield of 1.14%. Purely for dividend investing, there may be better candidates out there.
IPN's Dividend Yield is comparable with the industry average which is at 2.89.
With a Dividend Yield of 1.14, IPN pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.14% |
5.2 History
The dividend of IPN has a limited annual growth rate of 3.72%.
Dividend Growth(5Y)3.72%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
IPN pays out 25.90% of its income as dividend. This is a sustainable payout ratio.
The dividend of IPN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.9%
EPS Next 2Y3.8%
EPS Next 3Y4.44%
EPA:IPN (11/12/2025, 9:31:55 AM)
130.5
+0.3 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners15.12%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap10.94B
Revenue(TTM)3.76B
Net Income(TTM)447.90M
Analysts70
Price Target131.74 (0.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.14% |
Yearly Dividend1.2
Dividend Growth(5Y)3.72%
DP25.9%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.27%
PT rev (3m)2.1%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.44%
EPS NY rev (3m)4.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.09%
Revenue NY rev (3m)1.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.71 | ||
| Fwd PE | 11.79 | ||
| P/S | 2.91 | ||
| P/FCF | 21.21 | ||
| P/OCF | 12.19 | ||
| P/B | 2.59 | ||
| P/tB | 8.19 | ||
| EV/EBITDA | 6.01 |
EPS(TTM)10.27
EY7.87%
EPS(NY)11.07
Fwd EY8.48%
FCF(TTM)6.15
FCFY4.72%
OCF(TTM)10.71
OCFY8.2%
SpS44.86
BVpS50.46
TBVpS15.93
PEG (NY)1.89
PEG (5Y)1.45
Graham Number107.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.56% | ||
| ROE | 10.59% | ||
| ROCE | 18.07% | ||
| ROIC | 14.88% | ||
| ROICexc | 20.46% | ||
| ROICexgc | 77.25% | ||
| OM | 26.01% | ||
| PM (TTM) | 11.91% | ||
| GM | 83.32% | ||
| FCFM | 13.72% |
ROA(3y)9.04%
ROA(5y)10.56%
ROE(3y)14.84%
ROE(5y)18.77%
ROIC(3y)12.97%
ROIC(5y)15.34%
ROICexc(3y)20.33%
ROICexc(5y)25.52%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)15.75%
ROCE(5y)18.64%
ROICexgc growth 3Y-59.92%
ROICexgc growth 5Y-22.83%
ROICexc growth 3Y-29.05%
ROICexc growth 5Y-11.89%
OM growth 3Y-13.94%
OM growth 5Y-4.28%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.5 | ||
| Cap/Depr | 55.54% | ||
| Cap/Sales | 10.15% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 53.9% | ||
| Profit Quality | 115.14% | ||
| Current Ratio | 1.98 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 4.58 |
F-Score7
WACC7.89%
ROIC/WACC1.89
Cap/Depr(3y)131.36%
Cap/Depr(5y)124.73%
Cap/Sales(3y)11.81%
Cap/Sales(5y)11.18%
Profit Quality(3y)85.87%
Profit Quality(5y)89.99%
High Growth Momentum
Growth
EPS 1Y (TTM)12.24%
EPS 3Y4.15%
EPS 5Y8.79%
EPS Q2Q%44.4%
EPS Next Y6.71%
EPS Next 2Y3.8%
EPS Next 3Y4.44%
EPS Next 5Y5.58%
Revenue 1Y (TTM)9.45%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%9.67%
Revenue Next Year8.23%
Revenue Next 2Y6.1%
Revenue Next 3Y6%
Revenue Next 5Y4.58%
EBIT growth 1Y66.72%
EBIT growth 3Y-6.06%
EBIT growth 5Y1.3%
EBIT Next Year32.82%
EBIT Next 3Y13.53%
EBIT Next 5Y7.88%
FCF growth 1Y-33.64%
FCF growth 3Y-35.67%
FCF growth 5Y-17.46%
OCF growth 1Y-8.92%
OCF growth 3Y-0.07%
OCF growth 5Y7.84%
IPSEN / IPN.PA FAQ
What is the fundamental rating for IPN stock?
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA.
Can you provide the valuation status for IPSEN?
ChartMill assigns a valuation rating of 6 / 10 to IPSEN (IPN.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for IPSEN?
IPSEN (IPN.PA) has a profitability rating of 6 / 10.
What is the earnings growth outlook for IPSEN?
The Earnings per Share (EPS) of IPSEN (IPN.PA) is expected to grow by 6.71% in the next year.
Can you provide the dividend sustainability for IPN stock?
The dividend rating of IPSEN (IPN.PA) is 4 / 10 and the dividend payout ratio is 25.9%.